替罗非班在糖尿病并不稳定型心绞痛患者行PCI治疗中的疗效观察

目的评价血小板膜糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂替罗非班冠状动脉应用在糖尿病并不稳定型心绞痛患者行经皮冠状动脉植入术(PCI)治疗中的有效性和安全性。方法将82例糖尿病并不稳定型心绞痛行PCI治疗的患者随机分为治疗组42例和对照组40例。治疗组介入前冠状动脉内应用替罗非班,并继续静脉泵入36h,对照组不应用替罗非班。观察并比较2组术中冠状动脉血流情况、术后6个月内不良心血管事件发生情况及出血、血小板减少情况。结果治疗组PCI术中TIMI0～2级血流率为4.76%,低于对照组的20.00%;不良心血管事件总发生率为2.38%,低于对照组的27.50%,差异均有统计学意义(P<0.05)。治疗组总出血率为14.29%,对照组为5.00%,差异无统计学意义(P=0.467)。2组均未发生血小板减少。结论替罗非班可改善糖尿病并不稳定型心绞痛患者PCI术中血流,减少术后血栓形成、再发心绞痛等不良事件发生率,且安全性好。

Efficacy observation of tirofiban in PCI treatment of unstable angina among diabetes patients

Objective To evaluate the efficacy and safety of tirofiban in percutaneous coronary intervenstions（PCI） treatment of unstable angina among diabetes patients.Methods 82 patients with diabetes complicated with unstable angina who all accepted percutaneous coronary intervenstions（PCI） were selected randomly divided into treatment group（42 cases） and control group（40 cases）.The treatment group were given tirofiban via coronary before PCI and continued infusion by means of vein pump lasted 36 hours.The control group didn’t use tirofiban.The condition of coronary blood flow during PCI,incidence of adverse cardiovascular events（MACE） and condition of hemorrhage,thrombocytopenia during 6 months after PCI were observed and compared.Results The rate of TIMI grade 0～2 during PCI of the treatment group was 4.76%,lower than 20% of the control group;the total incidence of MACE of the treatment group was 2.38%,lower than 27.5% of the control group,the differences were statistically significant（P〈0.05）.The bleeding incidence of the treatment group was 14.29%,which of the control group was 5%,the difference was not statistically significant（P=0.467）.There was no thrombocytopenia in both groups.Conclusion Triofiban can improve the amount of blood flow during PCI and decrease the incidence of MACE such as thrombosis and reoccurred angina,and is more safety.